What is the recommended initiation protocol for Dilantin (Phenytoin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initiating Dilantin (Phenytoin) Therapy

The recommended protocol for initiating Dilantin (phenytoin) is an intravenous loading dose of 18-20 mg/kg at a maximum rate of 50 mg/min in adults, with close cardiac monitoring. 1

Intravenous Loading Dose Protocol

IV Administration

  • Loading dose: 18-20 mg/kg IV (maximum 1000 mg) 2, 1
  • Maximum infusion rate: 50 mg/min in adults, 1-3 mg/kg/min in children 1
  • Dilution: Use normal saline only (incompatible with glucose-containing solutions) 1
  • Equipment: Use in-line filter and infusion pump 2

Monitoring During IV Administration

  • Continuous cardiac monitoring is essential
  • Monitor blood pressure and respiratory function
  • Reduce infusion rate if heart rate decreases by ≥10 beats/min
  • Watch for adverse effects: hypotension, bradyarrhythmias, cardiac arrest, and extravasation injuries 2

Oral Loading Dose Protocol (When IV Not Feasible)

Oral Administration

  • Loading dose: 1 gram divided into three doses (400 mg, 300 mg, 300 mg) administered at two-hour intervals 3
  • Setting: Should be reserved for patients in a clinic or hospital setting where phenytoin serum levels can be closely monitored 3
  • Contraindications: Patients with history of renal or liver disease should not receive oral loading regimen 3

Maintenance Dosing

Adult Maintenance Dosing

  • Begin maintenance dosing 24 hours after loading dose 3
  • Typical regimen: 300 mg daily (100 mg three times daily) 3
  • Adjustment range: Can increase up to 200 mg three times daily if necessary 3
  • Once-daily option: If seizure control is established with divided doses, may consider 300 mg once daily using extended phenytoin sodium capsules only 3

Pediatric Maintenance Dosing

  • Initial dose: 5 mg/kg/day in 2-3 divided doses 3
  • Maintenance dose: 4-8 mg/kg/day 3
  • Maximum: Up to 300 mg daily 3
  • Children >6 years and adolescents may require adult dosing 3

Therapeutic Monitoring

  • Target serum level: 10-20 mcg/mL (total) or 1-2 mcg/mL (unbound) 1, 3
  • Time to steady-state: 7-10 days to achieve steady-state blood levels 3
  • Adjustment timing: Changes in dosage should not occur at intervals shorter than 7-10 days 3
  • Monitoring frequency: Frequent serum level determinations after loading dose 3

Special Considerations

  • When switching between IV and oral formulations, maintain the same total daily dose, accounting for bioavailability differences (IV is 100% bioavailable, oral is approximately 90%) 1
  • Monitor unbound phenytoin concentrations rather than total levels in patients with hypoalbuminemia, renal failure, or other conditions affecting protein binding 1
  • Elderly patients require lower or less frequent dosing due to decreased clearance 1
  • During pregnancy, monitor unbound phenytoin concentrations due to potential changes in protein binding 1

Common Pitfalls to Avoid

  1. Infusion rate errors: Exceeding the maximum infusion rate can cause cardiac arrhythmias and hypotension
  2. Dilution errors: Never mix phenytoin with glucose solutions
  3. Inadequate monitoring: Failure to monitor cardiac function during IV administration
  4. Formulation confusion: Different phenytoin products have different absorption characteristics; do not interchange brands without monitoring levels 3
  5. Dosage adjustment errors: Making changes more frequently than every 7-10 days can lead to toxicity due to the long half-life

If phenytoin fails or is contraindicated, alternative agents include valproate (20-30 mg/kg IV), levetiracetam (40-60 mg/kg IV), or phenobarbital (10-20 mg/kg IV) 1.

References

Guideline

Status Epilepticus Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.